DA
WST icon

Duality Advisers’s West Pharmaceutical WST Stock Holding History

Duality Advisers’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-660
Closed -$232K – 769
2023
Q4 		$232K Sell
660
-109
-14% -$38.6K 0.02% 536
2023
Q3 		$289K Buy
+769
New +$297K 0.03% 488
2023
Q1 		– Sell
-7,566
Closed -$1.78M – 792
2022
Q4 		$1.78M Sell
7,566
-11,058
-59% -$2.62M 0.2% 182
2022
Q3 		$4.58M Buy
18,624
+5,944
+47% +$1.81M 0.5% 41
2022
Q2 		$3.83M Buy
+12,680
New +$4.13M 0.38% 57
2021
Q4 		– Sell
-14,995
Closed -$6.37M – 709
2021
Q3 		$6.37M Buy
+14,995
New +$6.32M 0.49% 42
2020
Q4 		– Sell
-13,820
Closed -$3.8M – 755
2020
Q3 		$3.8M Buy
+13,820
New +$3.66M 0.24% 100

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Duality Advisers's WST Position: Q1 2024 in Review

Duality Advisers sold out of West Pharmaceutical (WST) in Q1 2024, closing a stake of 660 shares — an estimated $232K sold.

Duality Advisers first reported a position in WST in Q3 2020 and held it in 7 quarters. The position peaked at $6.37M in Q3 2021. 779 funds tracked by Wall St. Rank hold WST as of Q1 2024.

  • Duality Advisers reported no remaining West Pharmaceutical position as of Q1 2024 after selling out during the quarter.
  • Duality Advisers sold 660 West Pharmaceutical shares in Q1 2024, an estimated $232K.
  • Duality Advisers first reported a position in West Pharmaceutical in Q3 2020 and held it in 7 quarters.
  • Duality Advisers's West Pharmaceutical position peaked at $6.37M in Q3 2021.
  • 779 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2024.

Based on Duality Advisers's 13F filing for Q1 2024, filed 6 May 2024.